Lumexa Imaging Holdings Q3 2026 earnings
Revenue and Adjusted EBITDA grew, while GAAP net income improved from a loss to a profit driven by lower interest expense and a lower tax rate.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| EPS (GAAP) | $0.07 | +140.0% | +133.3% | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Net patient service revenue | $211.12M | +4.7% | 77.6% | — |
| Management fee and other revenue | $60.86M | +6.3% | 22.4% | — |
Margins and costs
- Gross margin 15.2% (prior 15.2%, change 0.0 pp)
- Operating expenses $266.71M (+9.1% YoY)
- One-offs in the quarter Fair market value adjustment on debt $654k; Transaction costs ($661k); Litigation and settlements $3.58M; Strategic initiatives and implementation $2.37M; Severance and executive recruiting $622k
- Effective tax rate 39.1% (prior-year 39.1%, year-to-date 43.5%)
- Non-GAAP bridge Adds back stock-based compensation, transaction costs, litigation, strategic initiatives, severance, fair market value adjustment, and amortization of basis difference; equity in earnings of unconsolidated affiliates are also adjusted.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Advanced Procedures | Record high | — | — | — |
| Center count | 190 total | — | — | — |
| Cash and cash equivalents | $90.01M | $69.71M | $4.75M | +29.1% |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Total revenues | $1.025B - $1.045B | $1.025B - $1.045B | — |
| Adjusted EBITDA | $235M - $245M | $235M - $245M | — |
| Adjusted EPS | $0.23 - $0.24 | $0.23 - $0.24 | — |
What drove it
- Revenue story Net patient service revenue grew 4.7% and management fees grew 6.3% year-over-year.
- EPS story EPS improved due to a lower tax rate and a narrower loss in prior-year periods, rather than revenue growth.
- One-off check Fair market value adjustment on debt $654k; Transaction costs ($661k); Litigation and settlements $3.58M; Strategic initiatives and implementation $2.37M; Severance and executive recruiting $622k.
The good
- Adjusted EBITDA margin expanded 2.4 pp sequentially to 23.0%
- Cash and cash equivalents increased 29.1% to $90.01M
The bad
- Net patient service revenue growth slowed to 4.7% from 5.1% in Q2
- Interest expense remains high at $15.67M
The ugly
- none
Open questions
- What is the specific amount of the fair market value adjustment on debt?
- What is the breakdown of the $3.58M litigation and settlements charge?
- What is the specific amount of the $2.37M strategic initiatives and implementation charge?
Full release
Lumexa Imaging Holdings (LMRI) earnings release, November 10, 2026
Lumexa Imaging Announces Third Quarter 2026 Results
RALEIGH, N. C., November 10, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the third quarter ended September 30, 2026.
“In Q3, we advanced our business in several meaningful ways while executing against our strategy. Advanced modalities reached a record high as a percent of our volumes, and our newer de novo cohorts continue to ramp on plan. We are actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “These achievements mark progress toward our long-term growth plans, and that progress is translating into strong, durable cash generation. We enter the fourth quarter confident in our ability to deliver for patients, partners, and shareholders.”
“We are leading a transformation in healthcare - delivering high-quality imaging in more convenient settings, more quickly and at meaningfully lower cost through our wholly owned centers and alongside health system partners, improving clinical and financial outcomes.”
Third Quarter 2026 Highlights
All comparisons are to the quarter ended September 30, 2025, unless otherwise noted
2026 Full Year Outlook:
Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026.
Lumexa Imaging Earnings Conference Call and Webcast
Lumexa Imaging will host a conference call to discuss its third quarter 2026 results on November 10, 2026 at 5:00 p.m. ET. The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.
Statement Regarding Use of
Non-GAAP
Financial Measures
This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use Adjusted EBITDA and
Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance;
(ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.
We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.
About Lumexa Imaging
Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and approximately 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.
Financial statements
Income Statement
Three Months Ended September 30, — (Unaudited) (in thousands)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | |
|---|---|---|
| REVENUES: | ||
| Net patient service revenue | 211,115 | 201,695 |
| Management fee and other revenue | 60,858 | 57,249 |
| Total revenues | 271,973 | 258,944 |
| OPERATING EXPENSES: | ||
| Cost of operations, excluding depreciation and amortization | 225,571 | 219,236 |
| General and administrative expenses | 30,025 | 17,081 |
| Depreciation and amortization | 10,331 | 9,654 |
| Loss on disposal of property and equipment | 779 | 623 |
| Total operating expenses | 266,706 | 246,594 |
| Equity in earnings of unconsolidated affiliates | 22,846 | 17,990 |
| INCOME FROM OPERATIONS | 28,113 | 30,340 |
| OTHER EXPENSES: | ||
| Interest expense | 15,674 | 30,577 |
| Fair market value adjustment on debt | 654 | |
| Total other expenses | 16,328 | 30,577 |
| INCOME (LOSS) BEFORE INCOME TAXES | 11,785 | -237 |
| Income tax provision | 4,607 | 3,264 |
| NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) | 7,178 | -3,501 |
| Weighted average shares outstanding: | ||
| Basic | 95,983,246 | 69,531,530 |
| Diluted | 96,256,077 | 69,531,530 |
| Net income (loss) per common share | ||
| Basic | 0.07 | -0.05 |
| Diluted | 0.07 | -0.05 |
Income Statement
Nine Months Ended September 30, — (Unaudited) (in thousands)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|
| REVENUES: | ||
| Net patient service revenue | 612,168 | 592,178 |
| Management fee and other revenue | 176,504 | 163,169 |
| Total revenues | 788,672 | 755,347 |
| OPERATING EXPENSES: | ||
| Cost of operations, excluding depreciation and amortization | 668,611 | 639,898 |
| General and administrative expenses | 74,757 | 53,262 |
| Depreciation and amortization | 30,336 | 27,984 |
| Loss on disposal of property and equipment | 892 | 477 |
| Total operating expenses | 774,596 | 721,621 |
| Equity in earnings of unconsolidated affiliates | 56,489 | 49,835 |
| INCOME FROM OPERATIONS | 70,565 | 83,561 |
| OTHER EXPENSES: | ||
| Interest expense | 48,227 | 90,523 |
| Loss on extinguishment and modification of debt | 1,053 | |
| Fair market value adjustment on debt | 654 | |
| Total other expenses | 49,934 | 90,523 |
| INCOME (LOSS) BEFORE INCOME TAXES | 20,631 | -6,962 |
| Income tax provision | 8,991 | 11,452 |
| NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) | 11,640 | -18,414 |
| Weighted average shares outstanding: | ||
| Basic | 95,983,242 | 69,527,181 |
| Diluted | 96,092,916 | 69,527,181 |
| Net income (loss) per common share | ||
| Basic | 0.12 | -0.26 |
| Diluted | 0.12 | -0.26 |
Income Statement
Three Months Ended September 30, — (Unaudited) (in thousands)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | |
|---|---|---|
| Net income (loss) | 7,178 | -3,501 |
| Depreciation and amortization | 10,331 | 9,654 |
| Income tax provision | 4,607 | 3,264 |
| Amortization of basis difference | 573 | 500 |
| Interest expense | 15,674 | 30,577 |
| Stock-based compensation | 12,339 | 8,312 |
| Loss on disposal of property and equipment | 779 | 623 |
| Fair market value adjustment on debt | 654 | |
| Severance and executive recruiting(1) | 622 | 365 |
| Strategic initiatives and implementation(2) | 2,365 | 1,198 |
| Transaction costs(3) | -661 | 2,899 |
| Litigation and settlements(4) | 3,578 | -14 |
| Other(5) | 362 | 728 |
| Adjustments for equity in earnings of unconsolidated affiliates(6) | 4,194 | 4,525 |
| Adjusted EBITDA | 62,595 | 59,130 |
Income Statement
Nine Months Ended September 30, — (Unaudited) (in thousands)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|
| Net income (loss) | 11,640 | -18,414 |
| Depreciation and amortization | 30,336 | 27,984 |
| Income tax provision | 8,991 | 11,452 |
| Amortization of basis difference | 1,678 | 1,500 |
| Interest expense | 48,227 | 90,523 |
| Stock-based compensation | 37,350 | 23,032 |
| Loss on extinguishment and modification of debt | 1,053 | |
| Loss on disposal of property and equipment | 892 | 477 |
| Fair market value adjustment on debt | 654 | |
| Severance and executive recruiting(1) | 2,253 | 2,538 |
| Strategic initiatives and implementation(2) | 5,849 | 3,084 |
| Transaction costs(3) | 2,628 | 10,363 |
| Litigation and settlements(4) | 4,780 | -142 |
| Other(5) | 444 | 886 |
| Adjustments for equity in earnings of unconsolidated affiliates(6) | 13,464 | 13,121 |
| Adjusted EBITDA | 170,239 | 166,404 |
Income Statement
Three Months Ended September 30, — (Unaudited) (in thousands)
| Three Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Components of “management fee and other revenues:” | ||||
| Fees for managing joint ventured outpatient sites and other third party services | 25,889 | 23,843 | ||
| Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa | 34,969 | 33,406 | ||
| Total revenues | 60,858 | 57,249 | ||
| Fees for managing joint ventured outpatient sites and other third party services | 73,490 | 64,497 | ||
| Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa | 103,014 | 98,672 | ||
| Total revenues | 176,504 | 163,169 | ||
Balance Sheet
September 30, 2026 — (Unaudited) (in thousands)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Cash and cash equivalents | 90,011 | 58,828 |
| Accounts receivable | 117,769 | 112,942 |
| Accounts receivable, related party | 22,570 | 18,893 |
| Other receivables | 33,174 | 19,015 |
| Prepaid expenses | 14,789 | 17,582 |
| Total current assets | 278,313 | 227,260 |
| Property and equipment, net of accumulated depreciation | 158,847 | 144,709 |
| Operating lease right-of-use assets | 74,833 | 76,555 |
| Investments in unconsolidated affiliates | 428,019 | 423,191 |
| Intangible assets, net of accumulated amortization | 38,582 | 41,335 |
| Goodwill | 807,554 | 807,554 |
| Other assets | 46,988 | 43,953 |
| TOTAL ASSETS | 1,833,136 | 1,764,557 |
| LIABILITIES AND EQUITY | ||
| Accounts payable | 20,382 | 44,857 |
| Accrued expenses and other current liabilities | 117,920 | 95,561 |
| Accounts receivable pledging arrangement | 2,322 | 1,599 |
| Current portion of long-term debt | 15,548 | 13,112 |
| Current portion of finance lease liabilities | 15,007 | 11,552 |
| Current portion of operating lease liabilities | 12,277 | 12,513 |
| Total current liabilities | 183,456 | 179,194 |
| Long-term debt, less current maturities | 821,524 | 819,029 |
| Long-term finance lease liabilities, less current maturities | 39,782 | 33,262 |
| Long-term operating lease liabilities, less current maturities | 70,377 | 71,437 |
| Deferred income taxes | 47,044 | 40,772 |
| Other liabilities | 36,870 | 34,740 |
| Total liabilities | 1,199,053 | 1,178,434 |
| EQUITY: | ||
| Common stock, $0.001 par value, 1,000,000,000 shares authorized, 96,062,177 shares issued and outstanding at September 30, 2026 and 96,109,927 shares issued and outstanding at December 31, 2025 | 96 | 96 |
| Additional paid-in-capital | 1,253,407 | 1,217,087 |
| Accumulated deficit | -619,420 | -631,060 |
| Total equity | 634,083 | 586,123 |
| TOTAL LIABILITIES AND EQUITY | 1,833,136 | 1,764,557 |
Cash Flow
Nine Months Ended September 30, — (Unaudited) (in thousands)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | 11,640 | -18,414 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | ||
| Depreciation and amortization | 30,336 | 27,984 |
| Amortization of operating lease right-of-use assets | 11,879 | 11,162 |
| Amortization of debt issuance costs | 2,161 | 4,337 |
| Amortization of cloud computing implementation costs | 1,332 | 271 |
| Unrealized fair market value adjustment on debt | 263 | |
| Write-off of debt issuance costs related to extinguishment of debt | 46 | |
| Equity in earnings of unconsolidated affiliates | -56,489 | -49,835 |
| Distributions from investments in unconsolidated affiliates | 55,028 | 41,223 |
| Loss on disposal of property and equipment | 892 | 477 |
| Deferred income taxes | 6,272 | 3,502 |
| Stock-based compensation | 37,350 | 23,032 |
| Other | -1,030 | |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | -4,827 | -7,206 |
| Accounts receivable, related party | -3,677 | 2,189 |
| Capitalized cloud computing implementation costs | -2,773 | -1,686 |
| Other receivables | -14,159 | -7,494 |
| Prepaid expenses | 2,094 | -6,369 |
| Other assets | -2,196 | -15,418 |
| Accounts payable | -24,475 | 5,007 |
| Accrued expenses and other current liabilities | 29,725 | -10,889 |
| Other liabilities | 2,605 | 7,700 |
| Operating lease liabilities | -11,453 | -9,602 |
| Net cash provided by (used in) operating activities | 70,544 | -29 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale or disposal of property and equipment | 196 | 794 |
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our guidance for full year 2026 and our assumptions underlying such guidance; and our ability to drive future growth and execute on our goals and strategies. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form
10-K for the year ended December 31, 2025 and our later dated Quarterly Reports on Form
10-Q, each as filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.
Investor Contact
Sue Dooley
Lumexa Imaging
Sue.Dooley@LumexaImaging.com
Media Contact elissa Weston
Lumexa Imaging
Melissa.Weston@LumexaImaging.com
Lumexa Imaging Q3 2026 Outpatient Volumes Highlights:
Note: Advanced Procedures includes MRI and CT modalities. As of September 30, 2026 Center count was 190 total, 87 JV and 103 consolidated.
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES